Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)

Summary

\[18 F\]fluorodeoxyglucose (18F-FDG) positron emission tomography-magnetic resonance imaging (PET/MRI) is a new hybrid imaging tool that has recently arrived in oncology, and is particularly promising. Its usefulness seems obvious in certain tumor types, but its place in the staging of cervical cancers has never been explored in a prospective trial to our knowledge. Previously, a comparative retrospective study from 2009 found a better sensitivity of PET fused to diagnostic MRI images compared to PET/CT (positron emission tomography/computed tomography) in the detection of metastatic lymph nodes (54 and 44% respectively). It was an a posteriori fusion of images, from images acquired by PET-CT.

Eligibility

Inclusion Criteria:

* Patients aged from 18 years old and over
* Patients with presumed cervical cancer of stages IB2 to IVA based on clinical data and pelvic MRI, undergoing pre-treatment assessment.
* For women of childbearing potential : Adequate contraception throughout study participation.

Note : enrollment in a concomitant clinical trial is authorized

Exclusion Criteria:

* Oncological history that could possibly interfere with imaging results interpretation, apart from cervical cancer
* Extra-nodal metastasis clinically or radiologically proven before study participation
* Contraindication to MRI or injection of contrast agents containing gadolinium
* Contraindication to lumbo-aortic lymphadenectomy
* Persons deprived of liberty
* Minor or patients placed under guardianship or supervision
* Patient under judicial protection
* Patient unable to consent

Conditions2

Browse More Trials